Artificial intelligence might solve a world of cost issues for medical science, but the results of a recent study suggest that the day has not yet come when hospitals and doctor’s offices can just feed data into a computer and expect a reliable and intelligible diagnosis.
In what represents the first patenting to emerge from Braincapture ApS, its chief executive officer, Tue Lehn-Schiøler, describes the development of a low-cost, portable electroencephalogram device designed to enhance neurological diagnostics in underserved communities around the world.
In just the second PCT filing published in the name of Newmanbrain SL, co-founders Carlos Belmonte and Joaquin Ibañez seek specific protection for the use of Newmanbrain’s functional near infrared spectroscopy system, Theia, in the diagnosis of attention deficit/hyperactivity disorder.